LCS
ABBV icon

Levin Capital Strategies’s AbbVie ABBV Stock Holding History

Levin Capital Strategies’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.91M Sell
27,460
-14,562
-35% -$3.13M 0.46% 58
2026
Q1 		$9.14M Buy
+42,022
New +$9.32M 0.69% 47
2023
Q4 		– Sell
-2,638
Closed -$393K – 248
2023
Q3 		$393K Hold
2,638
– – 0.05% 156
2023
Q2 		$355K Hold
2,638
– – 0.04% 159
2023
Q1 		$420K Hold
2,638
– – 0.05% 133
2022
Q4 		$426K Hold
2,638
– – 0.06% 135
2022
Q3 		$354K Sell
2,638
-500
-16% -$71.7K 0.05% 140
2022
Q2 		$481K Hold
3,138
– – 0.06% 132
2022
Q1 		$509K Hold
3,138
– – 0.05% 155
2021
Q4 		$425K Hold
3,138
– – 0.04% 185
2021
Q3 		$338K Sell
3,138
-12,420
-80% -$1.42M 0.03% 217
2021
Q2 		$1.75M Sell
15,558
-43,227
-74% -$4.87M 0.18% 74
2021
Q1 		$6.36M Sell
58,785
-265
-0.4% -$28.3K 0.68% 42
2020
Q4 		$6.33M Sell
59,050
-4,379
-7% -$421K 0.71% 38
2020
Q3 		$5.56M Sell
63,429
-6,045
-9% -$569K 0.73% 37
2020
Q2 		$6.82M Buy
69,474
+64,474
+1,289% +$5.68M 0.94% 32
2020
Q1 		$381K Buy
+5,000
New +$426K 0.06% 98
2019
Q4 		– Sell
-10,065
Closed -$762K – 210
2019
Q3 		$762K Buy
+10,065
New +$690K 0.08% 97
2016
Q2 		– Sell
-814,036
Closed -$46.5M – 337
2016
Q1 		$46.5M Sell
814,036
-1,590,903
-66% -$88.7M 0.84% 30
2015
Q4 		$142M Buy
2,404,939
+250,949
+12% +$14.5M 2.5% 11
2015
Q3 		$117M Buy
2,153,990
+285,345
+15% +$18.6M 2% 18
2015
Q2 		$126M Buy
1,868,645
+402,575
+27% +$26.3M 1.86% 17
2015
Q1 		$85.8M Buy
+1,466,070
New +$88.6M 1.29% 23

Other funds holding ABBV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Levin Capital Strategies's ABBV Position: Q2 2026 in Review

Levin Capital Strategies reduced its AbbVie (ABBV) stake by 35% in Q2 2026, selling an estimated $3.13M and leaving 27,460 shares worth $6.91M. The position accounts for 0.46% of the portfolio, ranked #58.

Levin Capital Strategies first reported a position in ABBV in Q1 2015 and has held it in 23 quarters since. The position peaked at $142M in Q4 2015. 4,193 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Levin Capital Strategies held 27,460 shares of AbbVie worth $6.91M as of Q2 2026.
  • Levin Capital Strategies sold 14,562 AbbVie shares in Q2 2026, an estimated $3.13M.
  • AbbVie made up 0.46% of Levin Capital Strategies's portfolio in Q2 2026, its #58 holding.
  • Levin Capital Strategies first reported a position in AbbVie in Q1 2015 and has held it in 23 quarters since.
  • Levin Capital Strategies's AbbVie position peaked at $142M in Q4 2015.
  • 4,193 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Levin Capital Strategies's 13F filing for Q2 2026, filed 31 Jul 2026.